Pegylated granulocyte colony-stimulating factor primary prophylaxis versus no prophylaxis in patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: a randomized, open-label, multicenter, phase 2 trial

This publication has 39 references indexed in Scilit:

• Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
  JAMA Oncology, 2024
• A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma
  European Journal of Cancer, 2022
• Pancreatic Cancer
  JAMA, 2021
• A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
  International Journal of Clinical Oncology, 2021
• The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis
  Scientific Reports, 2018
• A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer
  Cancer Chemotherapy and Pharmacology, 2018
• Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population
  Cancer Letters, 2017
• Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis
  Pancreatology, 2017
• Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma
  European Journal of Cancer, 2010
• The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK
  Applied Health Economics and Health Policy, 2009